The worldwide Castrate-resistant Prostate Cancer Market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa based on geography.
Due to an increase in product approvals, North America is anticipated to have a dominating position in the worldwide castrate-resistant prostate cancer market over the forecast period. For instance, on May 19, 2020, the U.S. Food and Drug Administration (FDA) approved olaparib (LYNPARZA), developed by the multinational biopharmaceutical company AstraZeneca, for adult patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after receiving prior treatment with enzalutamide or abiraterone.
Read More:
https://knackersblogger.blogspot.com/2023/03/castrate-resistant-prostate-cancer.html
